Diabetes and gout: Efficacy and safety of febuxostat and allopurinol

Diabetes, Obesity and Metabolism

Volumn 15, Issue 11, 2013, Pages 1049-1055

  Becker, M A ^a   Macdonald, P A ^b   Hunt, B J ^b   Jackson, R L ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b TAKEDA PHARMACEUTICALS   (United States)

Author keywords

Clinical trial; Diabetes mellitus; Drug utilisation

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; FEBUXOSTAT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BREAST DISEASE; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DERMATITIS; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; ECZEMA; FEMALE; GASTROINTESTINAL DISEASE; GENITAL SYSTEM DISEASE; GLUCOSE BLOOD LEVEL; GOUT; GYNECOLOGIC DISEASE; HEART ARRHYTHMIA; HEART INFARCTION; HEPATOBILIARY DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFECTION; INFESTATION; INNER EAR DISEASE; KIDNEY FUNCTION; LOW DRUG DOSE; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OBESITY; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VASCULAR DISEASE;

CLINICAL TRIAL; DIABETES MELLITUS; DRUG UTILISATION;

ADULT; AGED; AGED, 80 AND OVER; ALLOPURINOL; BODY MASS INDEX; COHORT STUDIES; COMORBIDITY; DIABETES COMPLICATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; INTENTION TO TREAT ANALYSIS; KIDNEY; LOST TO FOLLOW-UP; MALE; MIDDLE AGED; OBESITY; PATIENT DROPOUTS; RENAL INSUFFICIENCY; THIAZOLES; XANTHINE OXIDASE; YOUNG ADULT;

EID: 84885327019     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12135     Document Type: Article

References (33)

1. Zhang W, Doherty M, Bardin T et al. EULAR evidencebased recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312-1324.
2. Khanna D, Fitzgerald JD, Khanna PP et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacogic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012; 64: 1431-1446.
3. Li-Yu J, Clayburne G, Sieck M et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001; 28: 577-580.
4. Pascual E, Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis 2007; 66: 1056-1058.
5. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002; 47: 356-360.
6. Sundy JS, Baraf HSB, Yood RA et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011; 306: 711-720.
7. Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009; 36: 1273-1278.
8. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004; 51: 321-325.
9. Schumacher HR Jr, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 2009; 48: 188-194.
10. Becker MA, Jolly M. Hyperuricemia and associated diseases. Rheum Dis Clin North Am 2006; 32: 275-293.
11. Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilization in US veterans. Ann Rheum Dis 2008; 67: 1310-1316.
12. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007; 57: 109-115.
13. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007; 116: 894-900.
14. Fuldeore MJ, Riedel AA, Zarotsky V, Pandya BJ, Dabbous O, Krishnan E. Chronic kidney disease in gout in a managed care setting. BMC Nephrol 2011; 12: 36.
15. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76: 47-56.
16. Allopurinol U.S. Prescribing Information. Apotex Corp, Weston FL, 2006.
17. Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial 2007; 20: 391-395.
18. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001; 60: 981-983.
19. Stamp LK, O'Donnell JL, Zhang M et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 2011; 63: 412-421.
20. Annemans L, Spaepen E, Gaskin M et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008; 67: 960-966.
21. Riedel AA, Nelson M, Wallace K, Joseph-Ridge N, Cleary M, Fam AG. Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol 2004; 10: 308-314.
22. Lai HM, Chen CJ, Su BY et al. Gout and type 2 diabetes have a mutual inter-dependent effect on genetic risk factors and higher incidences. Rheumatology (Oxford) 2012; 51: 715-720.
23. Johnson RJ, Perez-Pozo SE, Sautin YY et al. Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes? Endocr Rev 2009; 30: 96-116.
24. Choi HK, De Vera MA, Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology (Oxford) 2008; 47: 1567-1570.
25. Becker MA, Schumacher HR, Espinoza LR et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010; 12: R63.
26. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895-900.
27. Kidney Disease Outcomes Quality Initiative (KDOQI). Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Part 9. Approach to chronic kidney disease using these guidelines. National Kidney Foundation 2002; 1-9.
28. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
29. Robert S, Zarowitz BJ, Peterson EL, Dumler F. Predictability of creatinine clearance estimates in critically ill patients. Crit Care Med 1993; 21: 1487-1495.
30. Sarawate CA, Brewer KK, Yang W et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006; 81: 925-934.
31. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994; 308: 81-106.
32. White WB, Faich G, Borer JS, Makuch RW. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol 2003; 92: 411-418.
33. Doherty M, Jansen TL, Nuki G et al. Why is this curable disease so seldom cured? Ann Rheum Dis 2012; 71: 1765-1770.